159 related articles for article (PubMed ID: 21404110)
21. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.
Egbelakin A; Ferguson MJ; MacGill EA; Lehmann AS; Topletz AR; Quinney SK; Li L; McCammack KC; Hall SD; Renbarger JL
Pediatr Blood Cancer; 2011 Mar; 56(3):361-7. PubMed ID: 21225912
[TBL] [Abstract][Full Text] [Related]
22. Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers.
Aquilante CL; Wempe MF; Sidhom MS; Kosmiski LA; Predhomme JA
Eur J Clin Pharmacol; 2013 Jul; 69(7):1401-9. PubMed ID: 23407853
[TBL] [Abstract][Full Text] [Related]
23. Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment.
Shilbayeh SA; Sy SK; Melhem M; Zmeili R; Derendorf H
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):387-94. PubMed ID: 27137148
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.
Tran A; Jullien V; Alexandre J; Rey E; Rabillon F; Girre V; Dieras V; Pons G; Goldwasser F; Tréluyer JM
Clin Pharmacol Ther; 2006 Jun; 79(6):570-80. PubMed ID: 16765145
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
Gréen H; Söderkvist P; Rosenberg P; Mirghani RA; Rymark P; Lundqvist EA; Peterson C
Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):130-7. PubMed ID: 19143748
[TBL] [Abstract][Full Text] [Related]
26. Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis.
Yan M; Fan X; Si H; Wang X; Wang Z; Wang Z; Lv X; Yin H; Jia Y; Jiang L; Xia Y; Liu Y
Cancer Chemother Pharmacol; 2022 Feb; 89(2):173-181. PubMed ID: 34988655
[TBL] [Abstract][Full Text] [Related]
27. Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery.
Sychev D; Minnigulov R; Bochkov P; Ryzhikova K; Yudina I; Lychagin A; Morozova T
High Blood Press Cardiovasc Prev; 2019 Oct; 26(5):413-420. PubMed ID: 31617197
[TBL] [Abstract][Full Text] [Related]
28. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.
Díaz-Molina B; Tavira B; Lambert JL; Bernardo MJ; Alvarez V; Coto E
Transplant Proc; 2012 Nov; 44(9):2635-8. PubMed ID: 23146479
[TBL] [Abstract][Full Text] [Related]
29. The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients.
Schoeppler KE; Aquilante CL; Kiser TH; Fish DN; Zamora MR
Clin Transplant; 2014 May; 28(5):590-7. PubMed ID: 24628014
[TBL] [Abstract][Full Text] [Related]
30. Individualized pharmacotherapy with paclitaxel.
Mielke S
Curr Opin Oncol; 2007 Nov; 19(6):586-9. PubMed ID: 17906456
[TBL] [Abstract][Full Text] [Related]
31. Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression.
Ufer M; Dilger K; Leschhorn L; Daufresne L; Mosyagin I; Rosenstiel P; Haesler R; Kuehbacher T; Nikolaus S; Schreiber S; Cascorbi I
Clin Pharmacol Ther; 2008 Jul; 84(1):43-6. PubMed ID: 18322448
[TBL] [Abstract][Full Text] [Related]
32. Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662.
Diekstra MH; Klümpen HJ; Lolkema MP; Yu H; Kloth JS; Gelderblom H; van Schaik RH; Gurney H; Swen JJ; Huitema AD; Steeghs N; Mathijssen RH
Clin Pharmacol Ther; 2014 Jul; 96(1):81-9. PubMed ID: 24566734
[TBL] [Abstract][Full Text] [Related]
33. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenetics of irinotecan metabolism and transport: an update.
Smith NF; Figg WD; Sparreboom A
Toxicol In Vitro; 2006 Mar; 20(2):163-75. PubMed ID: 16271446
[TBL] [Abstract][Full Text] [Related]
35. Incidence of genetic polymorphisms involved in lipid metabolism among Chinese patients with osteonecrosis of the femoral head.
He W; Li K
Acta Orthop; 2009 Jun; 80(3):325-9. PubMed ID: 19626470
[TBL] [Abstract][Full Text] [Related]
36. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.
Prytuła AA; Cransberg K; Bouts AH; van Schaik RH; de Jong H; de Wildt SN; Mathôt RA
Clin Pharmacokinet; 2016 Sep; 55(9):1129-43. PubMed ID: 27138785
[TBL] [Abstract][Full Text] [Related]
37. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.
Crettol S; Venetz JP; Fontana M; Aubert JD; Pascual M; Eap CB
Ther Drug Monit; 2008 Dec; 30(6):689-99. PubMed ID: 18978522
[TBL] [Abstract][Full Text] [Related]
38. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.
Gunes A; Spina E; Dahl ML; Scordo MG
Ther Drug Monit; 2008 Oct; 30(5):628-33. PubMed ID: 18708991
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 Polymorphisms on Tacrolimus Concentration in Chinese Renal Transplant Recipients.
Liu F; Ou YM; Yu AR; Xiong L; Xin HW
Genet Test Mol Biomarkers; 2017 Nov; 21(11):663-673. PubMed ID: 28945481
[TBL] [Abstract][Full Text] [Related]
40. Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy.
Nakagawa J; Takahata T; Chen Y; Saito K; Kamata K; Tachita T; Yamashita S; Saito K; Ueno K; Sato A; Sakuraba H; Niioka T
Cancer Chemother Pharmacol; 2023 Nov; 92(5):391-398. PubMed ID: 37610625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
